



P R E S S R E L E A S E

Lelystad, 29 June 2009

ENTITLEMENT TO REIMBURSEMENT OF ORALGEN® PRODUCTS CONTINUED

Biopharmaceutical company Fornix BioSciences N.V. (Euronext Amsterdam: AFORBI) announces that the Applications Judge of the District Court of The Hague has ruled in summary proceedings between Fornix's Allergy Division Artu Biologicals Europe B.V. and the Dutch State that reimbursement for the allergy products Oralgen® Pollen (Oralgen® Grass Pollen and Oralgen® Tree Pollen) and Oralgen® Mites must be continued until an irrevocable decision has been reached regarding the registration applications for these products and the subsequent applications for inclusion in the Medicine Reimbursement Scheme (MRS). The entitlement to reimbursement for these products is based on a special reimbursement scheme dating from 1993 that states that all allergen products that were in the market before 1993, as is the case with the aforementioned products, will be eligible for reimbursement pending the registration procedure.

Summary proceedings were brought due to uncertainty as to whether the products Oralgen® Pollen and Oralgen® Mites were still entitled to reimbursement on grounds of the transitional scheme in light of the intention of the Dutch Minister of Health, Welfare and Sport ("VWS") to revise the reimbursement system for allergen products effective 1 July 2009 and to bring it in line with the Dutch Medicines Act. The Applications Judge of the District Court of The Hague has ruled that the Dutch State is required to continue this reimbursement and to take all necessary measures to that end.

E N D O F P R E S S R E L E A S E

For further information: **Fornix BioSciences N.V.**
F.F. Roossien, CSO Fornix BioSciences N.V.
Tel. +31 (0) 320 26 77 99
Website: www.fornix.nl

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam, code AFORBI) which engages in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables.

Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has a workforce of around 130 and is active mainly in the Netherlands and Germany.

Its activities are carried out by two divisions, which in turn are made up of operating companies.

The Allergy Division, which consists of Artu Biologicals Europe and, since 1 June 2007, Artu Biologicals Deutschland, is the most profitable division. Its activities include the development, production and sale of a wide range of patient-friendly immunotherapeutic products, under the Oralgen®, Igevac® and other trade names. These products are used in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies of the efficacy of the various products.

The Medical Aids Division, which consists of Laprolan in Beuningen, engages in the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.